JP2022519007A5 - - Google Patents
Info
- Publication number
- JP2022519007A5 JP2022519007A5 JP2021534126A JP2021534126A JP2022519007A5 JP 2022519007 A5 JP2022519007 A5 JP 2022519007A5 JP 2021534126 A JP2021534126 A JP 2021534126A JP 2021534126 A JP2021534126 A JP 2021534126A JP 2022519007 A5 JP2022519007 A5 JP 2022519007A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- patient
- approximately
- less
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862779232P | 2018-12-13 | 2018-12-13 | |
| US62/779,232 | 2018-12-13 | ||
| US201962801450P | 2019-02-05 | 2019-02-05 | |
| US62/801,450 | 2019-02-05 | ||
| PCT/US2019/066150 WO2020123900A1 (en) | 2018-12-13 | 2019-12-13 | Deutetrabenazine for the treatment of dyskinesia in cerebral palsy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022519007A JP2022519007A (ja) | 2022-03-18 |
| JP2022519007A5 true JP2022519007A5 (enExample) | 2022-12-22 |
Family
ID=69173404
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021534126A Pending JP2022519007A (ja) | 2018-12-13 | 2019-12-13 | 脳性麻痺におけるジスキネジアを処置するためのデューテトラベナジン |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US11324732B2 (enExample) |
| EP (1) | EP3893876A1 (enExample) |
| JP (1) | JP2022519007A (enExample) |
| KR (1) | KR20210114946A (enExample) |
| CN (1) | CN113395966A (enExample) |
| AU (1) | AU2019395250A1 (enExample) |
| BR (1) | BR112021011386A2 (enExample) |
| CA (1) | CA3123393A1 (enExample) |
| CL (1) | CL2021001554A1 (enExample) |
| IL (1) | IL283920A (enExample) |
| MX (1) | MX2021007063A (enExample) |
| SG (1) | SG11202106344SA (enExample) |
| TW (1) | TWI784220B (enExample) |
| WO (1) | WO2020123900A1 (enExample) |
| ZA (1) | ZA202104786B (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2022519007A (ja) * | 2018-12-13 | 2022-03-18 | オースペックス ファーマシューティカルズ インコーポレイテッド | 脳性麻痺におけるジスキネジアを処置するためのデューテトラベナジン |
| US20240197714A1 (en) * | 2021-04-15 | 2024-06-20 | Neurocrine Biosciences, Inc. | Methods for the administration of certain vmat2 inhibitors |
| JP2024514873A (ja) * | 2021-04-15 | 2024-04-03 | ニューロクライン バイオサイエンシーズ，インコーポレイテッド | デューテトラベナジンおよびｃｙｐ２ｄ６阻害剤の併用投与のための方法 |
| WO2024090922A1 (ko) | 2022-10-24 | 2024-05-02 | 주식회사 디자인셀 | 줄기세포 배양액 및 상기로부터 분리된 세포외소포를 유효성분으로 포함하는 뇌신경계 질환의 예방 또는 치료용 약학적 조성물 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ591615A (en) * | 2008-09-18 | 2012-07-27 | Auspex Pharmaceuticals Inc | Benzoquinoline inhibitors of vesicular monoamine transporter 2 |
| AU2015200243B2 (en) * | 2009-06-24 | 2016-09-29 | Egalet Ltd | Controlled release formulations |
| US20120003330A1 (en) * | 2010-06-01 | 2012-01-05 | Auspex Pharmaceuticals, Inc. | Benzoquinolone inhibitors of vmat2 |
| JP6362601B2 (ja) | 2012-09-18 | 2018-07-25 | オースペックス・ファーマシューティカルズ・インコーポレイテッドＡｕｓｐｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | 小胞モノアミン輸送体２の重水素化ベンゾキノリン阻害剤の製剤薬物動態 |
| PL3265085T3 (pl) * | 2015-03-06 | 2022-11-07 | Auspex Pharmaceuticals, Inc. | Sposoby leczenia zaburzeń związanych z nieprawidłowymi ruchami mimowolnymi |
| TWI772382B (zh) * | 2017-03-15 | 2022-08-01 | 美商奧斯拜客斯製藥有限公司 | 氘代丁苯那嗪(deutetrabenazine)之類似物、其製備方法及用途 |
| JP2022519007A (ja) * | 2018-12-13 | 2022-03-18 | オースペックス ファーマシューティカルズ インコーポレイテッド | 脳性麻痺におけるジスキネジアを処置するためのデューテトラベナジン |
-
2019
- 2019-12-13 JP JP2021534126A patent/JP2022519007A/ja active Pending
- 2019-12-13 KR KR1020217021438A patent/KR20210114946A/ko not_active Abandoned
- 2019-12-13 TW TW108145866A patent/TWI784220B/zh active
- 2019-12-13 BR BR112021011386-0A patent/BR112021011386A2/pt not_active Application Discontinuation
- 2019-12-13 CN CN201980089635.4A patent/CN113395966A/zh active Pending
- 2019-12-13 WO PCT/US2019/066150 patent/WO2020123900A1/en not_active Ceased
- 2019-12-13 SG SG11202106344SA patent/SG11202106344SA/en unknown
- 2019-12-13 CA CA3123393A patent/CA3123393A1/en active Pending
- 2019-12-13 US US16/713,917 patent/US11324732B2/en not_active Expired - Fee Related
- 2019-12-13 AU AU2019395250A patent/AU2019395250A1/en not_active Abandoned
- 2019-12-13 EP EP19839001.5A patent/EP3893876A1/en not_active Withdrawn
- 2019-12-13 MX MX2021007063A patent/MX2021007063A/es unknown
-
2021
- 2021-06-11 CL CL2021001554A patent/CL2021001554A1/es unknown
- 2021-06-12 IL IL283920A patent/IL283920A/en unknown
- 2021-07-08 ZA ZA2021/04786A patent/ZA202104786B/en unknown
-
2022
- 2022-04-12 US US17/718,441 patent/US20220409597A1/en not_active Abandoned
-
2023
- 2023-06-28 US US18/343,197 patent/US20240082225A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Crosby et al. | Amantadine in Parkinson's disease | |
| JP7475398B2 (ja) | 医学療法におけるセマグルチド | |
| JP7436524B2 (ja) | ハンチントン病及びその症状を治療するためのプリドピジン及びその類似体を含む組成物 | |
| IL274943B2 (en) | Combination of a 4-pyrimidinsulfamide derivative with an SGLT-2 inhibitor for the treatment of endothelin-related diseases | |
| JP2019524897A5 (enExample) | ||
| JP2018513188A5 (enExample) | ||
| PT705099E (pt) | Utilizacao do modafinil para o tratamento da apneia do sono e problemas respiratorios de origem central | |
| TR201905098T4 (tr) | Amyotrofik lateral sklerozun tedavi edilmesi ya da amyotrofik lateral skleroz fazının ilerleyişinin önlenmesi için farmasötik ajan | |
| JP2022521233A5 (enExample) | ||
| Gupta et al. | Comparative evaluation of propofol versus dexmedetomidine infusion for hypotensive anesthesia during functional endoscopic sinus surgery: a prospective randomized trial | |
| JP2023548429A5 (enExample) | ||
| JP2022553888A5 (enExample) | ||
| CN104013638A (zh) | 当药黄素及其衍生物的用途 | |
| JPH08512311A (ja) | 慢性疲労症候群治療用ヒ素医薬 | |
| JP2024531799A5 (enExample) | ||
| JP6454436B1 (ja) | ペマフィブラートを含有する医薬 | |
| JP7016880B2 (ja) | チオトロピウムを有効成分として含有する近視予防、近視治療および／または近視進行抑制剤 | |
| JP2021532165A5 (enExample) | ||
| WO2013172339A1 (ja) | 腹圧性尿失禁予防剤及び／又は治療剤 | |
| CA2840521C (en) | Pharmaceutical composition for treating premature ejaculation and method for treating premature ejaculation | |
| CN115768430A (zh) | 伴随代谢异常的疾病或综合征中的肌力下降症状的改善剂或预防剂 | |
| US20230398090A1 (en) | Method of treating coronavirus infection by administration of ethyl mercury or thiol derivative thereof | |
| CN121443299A (zh) | 用于治疗脏器纤维化相关疾病的药物组合物和方法 | |
| Aoki | Peramivir | |
| CN116473974A (zh) | 杜伟利布在制备治疗特发性肺纤维化的药物中的应用 |